公开(公告)号：EP3323878A1

公开(公告)日：2018-05-23

申请号：EP16824084.4

申请日：2016-07-14

申请人： Daikin Industries, Ltd. ,  Otsuka Pharmaceutical Factory, Inc.

发明人： HIGUCHI, Tatsuya ,  KOMAZAWA, Kozue ,  MOHARA, Yoshiko ,  DEMPO, Takayuki ,  NISHIMURA, Masuhiro

IPC分类号： C12M3/00

CPC分类号： C12M23/20 ,  A61K35/28 ,  C09D127/18 ,  C09D127/20 ,  C09D129/10 ,  C12M23/14 ,  C12N5/0663

摘要： When mammal cells are administered by using a container whose surface in contact with the mammal cells is formed of a fluororesin material at least partially having a -CF 3 terminal group or a container whose surface in contact with the mammal cells is formed of a fluororesin material having a total number of non-fluorinated group terminals and -CF 2 H group terminals in the fluororesin of 70 or less per 1 × 10 6 carbon atoms, or mammal cells are stored or cultured in such a container, the cell adhesion on the container inner surface and the cell survival rate reduction can effectively be suppressed. Therefore, by using these containers, a mammal cell-containing liquid having a high concentration and a high proportion of living cells can be administered, stored or prepared, which contributes to regenerative medicine using the mammal cell-containing liquid (suspension liquid).